NeoLight, an empathy-driven medical device company that designs, engineers, and manufactures technologies to treat infants with life-threatening medical conditions, announces today interim data from an ongoing clinical study on the efficacy of NeoLight’s Skylife™, a neonatal phototherapy device recently cleared by the U.S. Food and Drug Administration (FDA) to treat hyperbilirubinemia, commonly known as Jaundice.
###
NeoLight is a medical device company that develops empathy driven, best-in-class technologies for treating preventable conditions in the newborn care market. Empathy driven solutions are a framework that has the doctor-nurse-mother-infant ecosystem at the center. It fosters the emotional connection that happens, thereby providing not just treatment but also providing care. Driving neonatal care beyond the traditional hospital setting, NeoLight is also creating a robust home market to treat neonatal conditions in the home. To learn more, visit www.theneolight.com and follow us on Twitter and LinkedIn.
